Pharma industry reports 58 deals worth $6.3 billion in February, says GlobalData

The healthcare industry reported 58 deals worth $6.3 billion in February 2022 as compared to the last 12-month average (February 2021 to January 2022) of 91 deals worth $19.5 billion, GlobalData has notified in a statement.

Biocon Biologics to acquire Viatris’ rights in biosimilars assets including its in-licensed portfolio, for up to $3.3 billion; Biohaven Pharmaceutical Holding Company to acquire Channel Biosciences, LLC and its Kv7 channel targetting platform, for a consideration of up to $1.2 billion; and Collegium Pharm Inc to acquire BioDelivery Sciences International Inc for an equity value of approximately $604 million, were the three major deals which contributed 82.5 per cent of the total deal value during February 2022, the statement said.

It also mentioned that the industry reported 116 VC deals worth $3.2 billion in February 2022, compared to the last 12-month average (February 2021 to January 2022) of 174 deals worth $5.3 billion.

Kallyope Inc, a biotechnology company raising $236 million in series D round of financing to advance clinical programmes in type-II diabetes, obesity and diseases of the gastro-intestinal barrier, as well as pipeline and platform development; Upstream Bio raising $200 million to develop drugs to treat inflammatory diseases; and Synthego Corp, a genome engineering company raising $200 million in growth capital to accelerate the field of CRISPR-based medicines from early-phase research to the clinic, were the major VC deals reported in February 2022, the statement concluded.